Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

7.634 +0.104 (+1.38%)
Streaming Delayed Price Updated: 10:27 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment
Via Investor Brand Network
Researchers Uncover Vital Clues on Drivers Behind Growth, Size of Brain Tumors
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion. 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast
Via Investor Brand Network
New Laws on Abortion May Complicate Cancer Treatment for Pregnant Patients
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients
Via Investor Brand Network
UC San Diego Offers New Radiation Therapy That Prevents Tumor Regrowth
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event
Via Investor Brand Network
Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
Via Investor Brand Network
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over... 
Via Benzinga
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
Via Investor Brand Network
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
Via Investor Brand Network
Topics Death
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
Via Investor Brand Network
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
Via Investor Brand Network
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
Via Investor Brand Network
Topics Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
Via Investor Brand Network
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.